Filing Flows › Adaptive Biotechnologies (ADPT) › Q1 2026
Adaptive Biotechnologies (ADPT) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 5, 2026
Adaptive Biotechnologies (ADPT) reported revenue of $70.9M for the first quarter 2026 (Q1 2026), +35% from a year earlier and -1% from the quarter before. Operating margin was -27.1%, net loss $20.0M (28.2% of revenue).
Adaptive Biotechnologies, Q1 2026: revenue $70.9M (+35% year over year), operating margin -27.1%, net loss $20.0M, operating cash flow −$9.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $70.9M | -1% | +35% |
| Operating profit | −$19.2M | — | — |
| Net earnings | −$20.0M | — | — |
| Operating cash flow | −$9.5M | -564% | — |
What changed
Revenue was $70.9M in Q1 2026, up 35% year over year and down 1% from the previous quarter.
Operating costs exceeded revenue by $19.2M, an operating margin of -27.1%. Total costs grew 10% against revenue growth of 35%. The fastest-growing cost line was General & admin (+21%). The quarter ended with a net loss of $20.0M, wider than the previous quarter's $13.6M loss.
Operating cash flow was −$9.5M. Non-cash charges added back $3.4M of depreciation and amortization and $11.9M of share-based compensation. Working capital and other items used $4.8M. Capital expenditures of $796K exceeded it, leaving free cash flow of −$10.3M.
Questions
What was Adaptive Biotechnologies' revenue in the first quarter 2026?
Adaptive Biotechnologies (ADPT) reported revenue of $70.9M for the first quarter 2026 (Q1 2026), +35% from a year earlier and -1% from the quarter before.
Was Adaptive Biotechnologies profitable in the first quarter 2026?
Operating loss was $19.2M (-27.1% of revenue) and net loss $20.0M.